Business Wire

Europe's GetVocal raises $26m to scale trustworthy conversational agents for enterprises

18.11.2025 10:00:00 CET | Business Wire | Press Release

Share

GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the closing of a $26 million Series A investment round led by Creandum with participation from Elaia and Speedinvest, bringing GetVocal’s total fundraising to $30 million. GetVocal will use the funding to fuel product innovation, market expansion, and hiring across Europe as the company accelerates its mission to help enterprises build hybrid human-AI workforces.

Founded in 2023 by AI entrepreneurs Roy Moussa and Antonin Bertin, GetVocal is headquartered in Paris, with a 60-strong team spread across Europe. It serves 23 markets, with a stronghold in France and Portugal, and a rapidly growing presence in the UK and DACH. The company tackles one of the biggest barriers to conversational AI adoption – the lack of trust and confidence in black-box autonomous systems – by building trustworthy, transparent, and governed AI agents that accelerate the customer experience (CX) market’s transition from “humans assisted by AI” to “AI powered by humans.”

Unlike other agents on the market, GetVocal’s large language models (LLMs) follow a strict business logic and are only deployed where AI works best – ensuring that humans are in the loop when crucial decisions happen. GetVocal’s CX platform acts as a single governing layer, orchestrating real-time collaboration between human and AI agents in a controlled environment, monitoring every conversation and alerting when human intervention is needed. Designed with the complexities of Europe in mind, the platform reliably supports the gradual shift of responsibilities to AI while maintaining complete transparency, auditability and compliance with the EU AI Act.

“Research by the MIT Media Lab shows that 95 percent of companies fail to get financial value from AI pilots because they lack the skills, processes, and governance to effectively integrate AI. Our customers are proudly in the five percent,” said GetVocal CEO and Co-founder Roy Moussa. “We look forward to restoring confidence in AI agents and offering Europe’s thriving enterprises a pragmatic solution to embed them in their customer experience operations. This funding will directly support the continued development of our hybrid workforce management capabilities and enable us to grow our international team and expand our commercial reach across Europe.”

Major brands such as Vodafone, Glovo, and Movistar already trust GetVocal to simplify and enhance complex customer service interactions, achieving tangible impact at scale, while a pilot is in progress at Deutsche Telekom. For example, Glovo grew its agent fleet from one to 80 AI agents in less than 12 weeks. Bruno Machado, Senior Operations Manager at Glovo, said, “Deploying GetVocal has transformed how we serve our community. From reactivating users to streamlining management, the results speak for themselves: a five-fold increase in uptime and a 35 percent increase in deflection, in just weeks. GetVocal is accelerating our growth and ensuring that we remain a platform users can always count on.”

Compared to existing enterprise solutions, GetVocal’s AI agents drive 31 percent fewer live escalations, 45 percent more self-service resolutions, and achieve a 70 percent deflection rate within three months of launch. This means customers can double efficiency gains while maintaining high satisfaction scores.

GetVocal’s AI agents are fully auditable, adhere to Europe’s strictest data sovereignty requirements and can be deployed on a self-hosted basis, making them ideal for enterprises seeking to prove compliance with the EU AI Act and similar emerging regulations.

“Black-box AI erodes accountability, and legacy contact-centre software locks organisations into rigid workflows unsuitable for day-to-day operations. GetVocal has built a winning platform that enables true automation while providing a level of control over agent behaviour that supports scaling without abandoning responsibility,” explained Hanel Baveja, Partner at Creandum, who will be joining GetVocal’s board.

About GetVocal

GetVocal is the conversational AI platform built for hybrid human-AI workforces. Enterprises rely on GetVocal to build, govern, and optimise hybrid agent fleets - monitoring customer support conversations in real time, intervening instantly, and safely shifting from human to AI service as automation skills evolve. With transparency and control at its core, GetVocal helps organisations modernise customer operations responsibly - without compromising on experience or trust.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251118820169/en/

Contacts

Media contact
Claire Ayles / Reka Agopcsa
Eleven Hundred Agency
T: +44 (0) 20 7688 5202
press@getvocal.ai

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye